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BACKGROUND. The goal of quality assurance in health care is to preserve and
improve patient care. Recently, RAND developed a set of evidence-based candidate
indicators for evaluating the quality of care for patients with localized prostate
carcinoma; however, the feasibility and sensitivity of these indicators have not
been tested in a clinical setting. The objectives of this study were to evaluate the
feasibility of measuring these quality indicators and to determine their sensitivity
to change in practice patterns over time.
METHODS. One hundred sixty-eight men who presented in either 1995 or in 2000
and were treated for localized prostate carcinoma were selected randomly from the
University of Michigan tumor registry. A combination of electronic data base
review and explicit chart review was used to assess the feasibility of measuring
compliance for each indicator. For each indicator in which assessment was feasi-
ble, compliance with the RAND indicators was determined for patients in both
years. Multivariate regression analysis was used to adjust for potential confounding
effects of disease stage, tumor grade, prostate specific antigen (PSA) level, patient
age, and therapy.
RESULTS. Based on review of available clinical data, measurement of compliance
was feasible for 19 of 22 RAND candidate quality indicators (86%). For five indi-
cators, significant differences in documentation (compliance) were detected be-
tween 1995 and 2000 (P  0.05). Treatment received and higher PSA levels were
associated independently with documentation of compliance for several indicators
(P  0.05).
CONCLUSIONS. Measurement of the majority of the RAND quality indicators for the
treatment of patients with localized prostate carcinoma was feasible, and improve-
ments in several indicators were observed between 1995 and 2000. Demonstration
of such variation, even within a single institution, suggests that the indicators are
sufficiently sensitive to detect differences in practice patterns. Cancer 2003;97:
1428 –35. © 2003 American Cancer Society.
DOI 10.1002/cncr.11216
KEYWORDS: prostate carcinoma, quality indicators, quality of care, quality assur-
ance.
In 2002, it is projected that 189,000 men will have been diagnosedwith prostate carcinoma, and the majority of these men will have
localized disease.1 Given the large number of patients who select
active treatment,2 the need for proper evaluation of the quality of care
for patients with localized prostate carcinoma is particularly germane.
Urinary, sexual, and bowel dysfunction are known complications of
both radical prostatectomy and external beam radiation therapy.
However, the reported complication rates for each treatment modal-
ity vary significantly among individual surgeons and institutions.3– 6
Although this variation may be explained, at least partially, by con-
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founding patient and disease characteristics (case-
mix), these disparate outcomes may also reflect differ-
ences in the quality of care.
The foundation for much of the emerging re-
search in quality assessment is based on Avedis Dona-
bedian structure-process-outcome paradigm.7 The
Donabedian paradigm is based on the ability of each
component of this model to provide insight regarding
the degree to which the best available treatment plans
were used in an optimal fashion.7,8 The structure do-
main evaluates the infrastructure and resources of the
care provider; the process domain examines what ac-
tually is done for patients and how this compares with
what should be done; and the outcome domain con-
siders the results attained by patients after medical
care.8,9
Historically, quality assessment initiatives have
been driven primarily by economic forces.9 However,
physicians have recognized the importance of criti-
cally analyzing patient outcomes and identifying fac-
tors that contribute to improvements in health care
delivery.10,11 Indeed, clinicians have played instru-
mental roles in the development and implementation
of benchmarks for clinical care as well as efforts to
bring local practices up to national or best-practice
standards.9,12
Recently, a multidisciplinary RAND team devel-
oped a set of candidate quality indicators for evaluat-
ing the quality of care for men with localized prostate
carcinoma. Those results are summarized in a report
entitled Prostate cancer patient outcomes and choice of
providers: development of an infrastructure for quality
assurance13 and available free on line (http://www.
rand.org/publications/MR/MR1227/). Based on liter-
ature review, patient focus groups, expert interviews,
and a RAND consensus panel, the project established
a measurement framework with a group of 22 indica-
tors proposed for use in quality assessment. The
RAND indicators provide a basis for assessing quality
care for patients with localized prostate carcinoma,
although the indicators have not been validated to
date in a clinical setting. Therefore, the objectives of
this study were 1) to evaluate the feasibility of mea-
suring compliance with the 22 RAND candidate qual-
ity indicators in a hospital setting; and 2) for indicators
for which assessment was feasible, to determine the
sensitivity to changes in patterns of care.
MATERIALS AND METHODS
Under Institutional Review Board (IRB) approval, a
cross-sectional review of care for patients with local-
ized prostate carcinoma was performed for two sepa-
rate calendar years (1995 and 2000), representing early
and contemporary care for patients with prostate car-
cinoma at the University of Michigan. One hundred
patients with localized prostate carcinoma who pre-
sented to our institution in each of these 2 years were
selected randomly from the hospital tumor registry for
chart abstraction. Thirty-two of 200 randomly selected
patients were excluded from the study. Exclusion cri-
teria included incidental prostate adenocarcinomas
discovered at the time of cystoprostatectomy per-
formed for urothelial carcinoma, primary therapy
other than radical prostatectomy or external radiation
therapy, treatment at another institution, and missing
patient medical records. Based on these criteria, 19
patients, including 8 patients whose paper medical
records could not be located (and electronic medical
records were not yet instituted), were excluded from
the 1995 cohort, and 13 patients were excluded from
the 2000 cohort.
The RAND quality indicators include 4 measures
of structure (S1–S4), 12 measures of process (P1–P12),
and 6 measures of outcome (O1–O6) (Table 1).13 A
combination of electronic and paper chart review,
along with data extraction from an IRB-approved
prostate cancer data base, was utilized for our first
objective of assessing the feasibility of measuring the
22 candidate quality indicators. These data sources
were reviewed for documentation of each quality in-
dicator (Table 1). For the purpose of this study, mea-
surement of a particular quality indicator was consid-
ered feasible only if explicit documentation was
identified for at least one patient. For each indicator
for which measurement of compliance was feasible,
the proportion of patients with documentation (of
compliance) was then reported and stratified by year.
A chart abstraction tool was created in Microsoft Ac-
cess software to record all relevant data. All chart
reviews were performed by two independent investi-
gators (D.C.M. and J.R.) who were not involved with
the care of the patients.
Feasibility assessment for several of the candidate
indicators (S1–S3) was based on institutional stan-
dards and resources (Table 1). In addition, compliance
with indicator S4 was measurable for any given patient
by review of our prostate cancer data base. For each
structure measure, the corresponding resources
and/or services have been available for all patients at
the University of Michigan since at least 1995. There-
fore, measurement of compliance with each structure
indicator was feasible for all patients who were in-
cluded in our analysis.
Feasibility assessment for several process mea-
sures (P8, P13, and P14) required examination of pa-
per and/or electronic medical records (Table 1). Pro-
cess measure P8 assessed whether or not the patient
was presented with the various treatment options for
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localized prostate carcinoma as well as the risks of
therapy. Measurement of this indicator was feasible,
in that compliance can be inferred from a single sen-
tence in the clinician’s note such as, “treatment op-
tions and their associated risk were discussed in detail
with the patient.” Similarly, feasibility assessment for
measures P13 and P14 also required explicit review of
electronic and paper medical records, because this
information was not available in our data base. For
this measure, letters of communication from treating
physicians to primary care providers were deemed
sufficient to achieve compliance, confirming the mea-
surability of P14.
In contrast, the measurement of one process in-
dicator (P9) and several outcome indicators (O17, O18,
O19, and O20) was feasible only by review of our
prostate cancer data base (Table 1), because the doc-
umentation necessary to confirm or refute compliance
TABLE 1












S1 No. of patients treated (volume) Xe — — —
S2 Availability of conformal RT Xe — — —
S3 Availability of psychological counseling Xe — — —
S4 Knowledge of treating institution outcomes — — — Xe
Process indicators
P5 Pretreatment PSA, DRE, Gleason score — X X Xe
P6 Documentation of pretreatment urinary, sexual, and bowel
function
— — — Xe
P7 Assessment of family history of prostate carcinoma — X X Xe
P8 Presentation of treatment alternatives; consultation with alternative
providers; discussion of risks of therapy
— Xe Xe —
P9 Adherence to practice protocol of the College of American
Pathologists Cancer Committee
— — — Xe
P10 Use of immobilization, CT planning and optimal dosing (68–72 Gy)
for patients undergoing conventional external RT
NFf NFf NFf NFf
P11 Use of immobilization, CT planning, rectal protection and optimal
dosing (70–80 Gy) for patients undergoing high-dose conformal
RT
NFf NFf NFf NFf
P12 For RT: Use of high-energy linear accelerator ( 10 MV) NFf NFf NFf NFf
P13 At least two follow-up visits with the treating physician in the first
year posttherapy
— Xe Xe —
P14 Documentation of communication with primary care provider or
provision of continuing care
— Xe Xe —
P15 Operative blood loss — X X Xe
P16 Use of clinical and pathologic TNM staging — X X Xe
Outcome indicators
O17 Primary treatment failure indicated by three consecutive increases
in PSA after RT or any detectable PSA after RP
— — — Xe
O18 After RT: Hospitalization, medical or surgical, treatment for cystitis,
proctitis, hematuria, or rectal bleeding
— — — Xe
O19 After RT or RP: Hospitalization, medical or surgical treatment for
bladder neck contracture/urethral stricture
— — — Xe
O20 Acute surgical complication rate — — — Xe
O21 Patient assessment of urinary, sexual, and bowel function after RT
or RP using a validated survey instrument
— — — Xe
O22 Patient satisfaction with treatment choice, continence, and potency — — — Xe
RT: radiation therapy; PSA: prostate specific antigen DRE: digital rectal examination; CT: computed tomography; NF: not feasible; Gy: grays; RP: radical prostatectomy.
a Institutional refers to the availability of resources maintained by the institution.
b Paper medical record refers to the official hard-copy medical record maintained by the Medical Records Department.
c Electronic medical record refers to the official computer-based medical record maintained by the Medical Records Department.
d Prostate cancer data base refers to the research data base maintained by the Department of Urology for clinical research and quality assurance.
e Primary source of documentation
f Measurement of compliance was not feasible based on a review of the available medical records data or the prostate cancer data base.
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with each of these measures was contained therein.
P9, for instance, evaluates an institution’s adherence
to the prostate carcinoma practice protocol of the
College of American Pathologists (CAP) Cancer Com-
mittee.14 For the purposes of this study, compliance
with this indicator could be measured by review of the
abstracted pathology report for each patient in our
prostate cancer data base. Notably, there are several
minor elements of this protocol that are not docu-
mented routinely for patients at our institution (ure-
thral obstruction in prostatectomy specimens and ex-
tracapsular extension for pathologic lymph nodes).
Inclusion of these elements was not considered nec-
essary for compliance, because they comprise only a
limited proportion of the entire CAP protocol; further-
more, these findings were documented when present.
Outcome measures O17, O18, O19, and O20 evaluate
biochemical recurrence and complication rates after
therapy. The feasibility of measuring these indicators
was determined by review of our electronic data base.
A data management specialist reviewed each clinic
note for patients who were treated with radiation ther-
apy or radical prostatectomy, and relevant informa-
tion, such as recent prostate specific antigen (PSA)
levels and therapy-related complications, were identi-
fied and entered accordingly. Therefore, measurement
of compliance with O17, O18, O19, and O20 was fea-
sible, because the rigorous chart review process uti-
lized to maintain our data base captures the occur-
rence of significant clinical events, including
biochemical recurrences, therapy-related complica-
tions, and/or hospitalizations.
Three of the candidate indicators (P6, O21, and
O22) assessed quality-of-life issues and patient satis-
faction. The validated instrument currently in use at
the University of Michigan for patient assessment of
urinary, sexual, and bowel function after primary ther-
apy is the Expanded Prostate Cancer Index Composite
(EPIC).15 EPIC results are maintained routinely in our
prostate cancer data base. Therefore, measurement of
compliance with candidate indicators P6, O21, and
O22 was feasible by querying the prostate cancer data
base (Table 1).
Feasibility assessment for several other RAND in-
dicators (P5, P7, P10, P11, P12, P15, and P16) was
accomplished by a combination of electronic data
base review and explicit chart review (Table 1). Mea-
surement of compliance with process indicators P5,
P7, P15, and P16 was feasible primarily by review of
our prostate cancer data base. P5 assessed pretherapy
documentation of serum PSA level, digital rectal ex-
amination (DRE) findings, and Gleason sum. These
data were verified for nearly all patients by electronic
query of our prostate cancer data base. In patients for
whom one of these staging parameters was not avail-
able in our data base, explicit review of the patient’s
electronic and paper records yielded the necessary
documentation (confirmation of compliance). Docu-
mentation of family history assessment (P7), operative
blood loss (P15), and use of clinical and pathologic
TNM staging (P16) also were determined primarily
from electronic data base review. Once again, in pa-
tients for whom a field was blank in our data base,
explicit chart review was undertaken to confirm or
refute compliance with each of these process mea-
sures.
Candidate indicators P10, P11, and P12 reviewed
several aspects of the quality of radiation therapy pro-
vided for patients with localized prostate carcinoma.
Evaluation of the indicator P10 was not possible at our
institution, because no patients who were included in
our analysis received conventional external radiation
therapy.
The second objective of this study was to compare
differences in compliance between 1995 and 2000 for
those indicators for which assessment was feasible.
For each indicator for which a change in the docu-
mentation (compliance) was observed, bivariate com-
parison of the proportions between the 2 years was
performed using the Fisher exact test. Multivariable
logistic regression analysis was then used to adjust for
potential confounding effects due to differences in
patient age (years), clinical stage (T1 vs. T2 or higher),
biopsy grade (Gleason sum), pretreatment PSA level
(ng/mL), and treatment received (radical prostatec-
tomy vs. external beam radiation therapy).16 All hy-
pothesis testing was done at the 5% significance level,
and all statistical analyses were performed using SAS
software (version 8.0; SAS Institute, Inc., Cary, NC).
RESULTS
Table 2 summarizes the demographics, clinical stage,
and treatment for the final cohort of 168 patients who
were included in the analyses. These characteristics
did not differ by year (all P values  0.05).
Feasibility of Measuring Compliance with the RAND
Candidate Indicators
First, the feasibility of measuring compliance with the
22 RAND candidate quality indicator variables was
assessed. Measurement of compliance was feasible for
several of the RAND structural indicators (S1–S3), be-
cause they simply reflected available institutional re-
sources and services (Table 1). For example, the sec-
ond structure measure (S2) evaluates the availability
of conformal radiation therapy at the treating institu-
tion. At our institution, conformal radiation is pro-
vided as the standard of care for patients undergoing
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radiation therapy since 1986. Therefore, this indicator
is considered measurable in all patients, because it is
available to all patients who pursue radiation therapy.
Measurement of compliance with the majority of
the indicators (S4, P5–P9, P13–P16, and O17–O22) was
feasible using a combination of electronic data base
and/or explicit review of the official medical records
(paper and electronic) (Table 1). Assessment of pre-
treatment and posttreatment urinary, sexual, and
bowel function (P6 and O21) was feasible only by
review of our prostate cancer data base. In general,
although thorough, explicit chart review yielded doc-
umentation of most of the indicators, our study was
facilitated greatly by the availability of a prostate can-
cer data base.
Measurement of compliance was not feasible for
three of the RAND process indicators (P10, P11, and
P12). Feasibility assessment for process indicator P10
was not possible because no patients in this study
received conventional radiation therapy. In addition,
measurement of compliance with process measures
P11 and P12 was not feasible, because the clinical data
(i.e., use of immobilization, computed tomographic
planning, and rectal protection) required to confirm
or refute compliance with these indicators is not
maintained routinely in either the official medical
record or our prostate cancer data base.
Sensitivity of the RAND Indicators to Detect Changes in
Practice Patterns
Several of the RAND candidate indicators (S1–S4, P9,
P15, O17–O20, and O22) had identical levels of com-
pliance (either 0% or 100%) both in 1995 and in 2000.
In contrast, there were several process and outcome
measures (P6 –P8, P13, P14, P16, and O21) for which
changes in compliance were detected between 1995
and 2000. For those indicators for which differences
were observed, the proportion of patients with docu-
mentation (of compliance) in each year and the cor-
responding statistical significance are presented in
Figure 1. Notably, although no patients had compre-
hensive documentation of pretreatment urinary, sex-
ual, and bowel function (P6) in 1995, many patients
did have documentation for one or two of these do-
mains. For the purposes of our analyses, this was
considered insufficient documentation to achieve
compliance with indicator P6.
Multivariable logistic regression models were con-
structed for each indicator for which changes in prac-
tice patterns were noted. For several indicators (P6,
P7, P13, and O21), we found that higher PSA level and
type of therapy received were associated indepen-
dently with compliance (Tables 3, 4). Patient age, clin-
ical stage, and biopsy grade did not affect compliance
with these candidate indicators.
DISCUSSION
Patients and advocacy groups are increasingly inter-
ested in the documentation of medical care quality.10
In addition, the government and major medical soci-
eties have invested tremendous effort in quality assur-
ance, as evidenced by the rigorous standards estab-
lished and enforced by routine Joint Commission on
Accreditation of Healthcare Organizations audits. The
universal goal of all such initiatives is to establish
standards that optimize the quality of patient care.
TABLE 2




(n  81 patients)
2000
(n  87 patients)
Mean  SD age (yrs) 63.2  7.3 60.5  9.5
Mean  SD pretreatment PSA (ng/dL) 8.1  9.1 8.8  10.0





Prostatectomy (%) 77.8 78.2
a SD: standard deviation; PSA: prostate specific angiten.
FIGURE 1. Compliance with 7 of 22 RAND indicators varied between 1995
and 2000. Compliance with structure indicators S1–S4; with process indicators
P5, P9, P10, P11, P12, and P15; and with outcome indicators O17, O18, O19,
and O20 was 100% in both years; whereas compliance with outcome indicator
O22 was 0% in both years.
1432 CANCER March 15, 2003 / Volume 97 / Number 6
Recently, RAND developed 22 candidate indica-
tors that provide an objective framework for measur-
ing and monitoring quality of care for patients under-
going therapy for localized prostate carcinoma. The
indicators are evidence based and are consistent with
the principles of the recent National Cancer Policy
Board report concerning the assessment of quality
care for oncology patients.13 The RAND report recom-
mended performing additional studies before the
RAND criteria can be considered the infrastructure for
quality care assessments in patients with prostate car-
cinoma. In the current study, we evaluated the feasi-
bility of measuring compliance with the 22 RAND
candidate quality indicators in a hospital setting and
determined their sensitivity to changes in the care of
patients with localized prostate carcinoma.
The availability of electronic data sources played a
vital role in documenting compliance with many of
the RAND candidate indicators. We took advantage of
the existing prostate cancer data base at the University
of Michigan to collect data for many of the RAND
process measures. Specific information abstracted
from the data base included documentation of pre-
treatment PSA level, Gleason sum, clinical stage, and
form of therapy. These data have been used previously
to identify determinants of better health outcomes
after patients are treated for prostate carcinoma.17–19
Our results support the concept that development and
maintenance of comprehensive, longitudinal data
bases can substantially augment and simplify the doc-
umentation of quality indicators. In sum, through a
process of explicit review of both medical records and
existing data bases, we demonstrated that, for patients
with localized prostate carcinoma, measurement of
compliance was feasible for 19 of 22 RAND candidate
indicators. The feasibility of measuring compliance
was unambiguous for most of the indicators and sup-
ports their application in future quality assessment
studies.
Between 1995 and 2000, based on the documen-
tation in available clinical data, changes in compli-
ance were detected for several of the process indica-
tors. During this interval, we demonstrated
significantly improved compliance with assessment of
family history of prostate carcinoma (P7), frequency of
posttherapy follow-up visits (P13), and communica-
tion with primary care physicians (P14) (P  0.05 for
each). Moreover, we identified documentation of pre-
treatment urinary, sexual, and bowel function (P6) as
a deficiency in our process of care. Indeed, compli-
ance with documentation of pretreatment function
was lacking for all patients who were treated in 1995;
however, 43% of patients were in compliance with this
indicator in 2000. This improvement coincides with
our current practice, beginning in July 2000, of rou-
tinely administering the EPIC questionnaire prior to
radical prostatectomy.
In both 1995 and 2000, 100% compliance with
documentation was achieved for four of six outcome
indicators (O17–O20). Documentation of these events
TABLE 3
Quality Indicator for which Compliance Was Associated Significantly with Higher Pretreatment Prostate Specific Antigen Levelsa
Indicator RAND quality indicator
Quartiles of pretreatment PSA levels (ng/mL)
Q1 (0.1–3.4) Q2 (3.5–5.7) Q3 (5.8–9.7) Q4 (9.8–73.7)
P6 Documentation of pretreatment urinary, sexual, and bowel function 27% 30% 24% 7%
a Percentages represent the proportion of patients in compliance with this indicator.
TABLE 4
Quality Indicators for which Compliance Was Associated Significantly with Treatment Received (P < 0.05)a
Indicator RAND quality indicator
Treatment received (%)
Prostatectomy External radiation
P6 Documentation of pretreatment urinary, sexual and bowel function 28 3
P7 Documentation of family history 64 97
P13 At least two follow-up visits after therapy 90 74
O21 Patient assessment of urinary, sexual, and bowel function after RT
or RP using a validated survey instrument
31 0
RT: radiation therapy; RP: radical prostatectomy.
a Percentages represent the proportion of patients in compliance with each indicator.
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(biochemical failures and complications of surgical
and/or radiation therapy) is maintained rigorously in
readily accessible data bases, as noted above. It may
be relevant to point out that the RAND report does not
specify an optimal follow-up period for tracking ther-
apeutic failures and complications. In this context,
clarification of an optimal follow-up interval will en-
hance the validity of these indicators and will facilitate
the assessment of compliance with these outcome
measures in future investigations.
However, we also identified several weaknesses in
our institutional approach to outcomes assessment, as
reflected in our level of compliance with indicators
O21 and O22. In 1995, no validated survey instruments
were in use at our center for patient assessment of
urinary, sexual, and bowel function after treatment
with radiation therapy or radical prostatectomy (O21).
Thus, although its measurement is feasible, compli-
ance with this indicator was absent uniformly in 1995.
During the intercurrent period, our interest in mea-
suring outcomes led to the development of novel,
validated instruments for this purpose (EPIC).15 Ac-
cordingly, compliance with documentation of post-
treatment function increased from 0% to 46% between
1995 and 2000 (P  0.0001). Now, health-related qual-
ity-of-life data are obtained routinely for all patients
treated at our institution to further enhance our un-
derstanding of functional outcomes after surgery.
Consequently, we anticipate that the nearly all pa-
tients who undergo radical prostatectomy at the Uni-
versity of Michigan in subsequent years will have doc-
umentation, using a validated instrument, of both
preoperative and postoperative urinary, sexual, and
bowel function. Efforts to achieve similar compliance
among patients who receive radiation therapy cur-
rently are underway but have not yet achieved uni-
form implementation.
Another area for potential quality improvement
relates to assessment of patient satisfaction (O22). Al-
though measurement of this indicator was feasible,
the observed lack of compliance with indicator O22
reflects the absence of validated tools for evaluating
posttreatment patient satisfaction with their overall
care as well as their oncologic and functional out-
comes. Thus, efforts to systematically measure patient
satisfaction as an indicator of quality care must in-
clude the development of a validated instrument for
this purpose.
In this study, we assumed that practice patterns at
our institution changed between 1995 and 2000. In-
deed, during this period, assessment of outcomes
prompted substantial changes in the process of care
for patients with localized prostate carcinoma.18 –21 In
this context, the demonstrated variation in several of
the candidate indicators reflects these changes in
practice patterns and supports the concept that the
RAND indicators are potentially sensitive to differ-
ences in quality of care. Moreover, the ability to detect
such variation within a single institution suggests that
the proposed quality indicators may be useful tools for
large-scale, interinstitutional comparisons of quality
care.
However, other factors also may affect quality of
care and should be considered in conjunction with
these indicators. In our study, we observed that higher
pretreatment PSA levels were associated with whether
or not pretreatment urinary, sexual, and bowel func-
tion were documented, indicating that patients with
higher PSA levels were less compliant with our pro-
spective quality-of-life evaluative studies. Treatment
received also was associated with compliance for sev-
eral of the candidate indicators, suggesting that phy-
sician bias or specialty bias may affect documentation
or performance of these quality indicators. Taken to-
gether, these finding substantiate the importance of
controlling for various disease-related, physician-re-
lated, and therapy-related factors when evaluating
quality of care.
Several limitations to this study merit discussion.
First, the RAND report did not propose standards for
documentation of compliance with each indicator.
Therefore, it was necessary for us to establish institu-
tion specific standards. Without clear guidelines for
documenting compliance, the reliability for certain
indicators may be limited in future multiinstitutional
studies. In addition, the absence of such guidelines
may limit the ability of nonphysician or nonmedical
personnel to abstract this information from the chart,
a transition that will be critical to the widespread
implementation of assessments of quality care for pa-
tients with prostate carcinoma. Indeed, future studies
should compare, on a larger scale, the findings of
physician and nonphysician abstracters to ensure the
validity and reliability of the data.
A second limitation to consider relates to patho-
logic evaluation of prostatectomy specimens. In this
study, we documented compliance with the CAP Pros-
tate Cancer protocol for all patients. Two minor ele-
ments from this protocol were not documented rou-
tinely but, instead, were reported only when present.
This suggests a need to modify the CAP protocol as a
quality indicator to make it more practical (P6).
Our inability to measure compliance with candi-
date indicators P10, P11, and P12 also merits further
deliberation. Each of these indicators evaluates the
quality of radiation therapy provided for patients with
localized prostate carcinoma. Despite a thorough re-
view of electronic and paper medical records, as well
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as our prostate cancer data base, measurement of
compliance was not feasible for these indicators.
Thus, although compliance with chemotherapy plan-
ning, immobilization, rectal protection (P11), and the
use of a high-energy accelerator (P12) may have been
achieved based on institutional protocols, we were
unable to confirm or refute this for any patient, de-
spite a rigorous review of available clinical data. This
suggests that, when they are performed, routine doc-
umentation of these radiotherapeutic details will be
necessary before they are established as indicators of
quality.
A final limitation relates to insufficient detail in
assessing pretreatment patient function. Although
compliance with documentation of pretreatment uri-
nary, sexual, and bowel function (P6) was lacking uni-
formly in 1995, the vast majority of patients had doc-
umentation for one or two of these domains. However,
this distinction cannot be made with indicator P6 in
its current form, because compliance with this indi-
cator requires documentation of urinary, sexual, and
bowel function. Therefore, P6 may underestimate pre-
therapy assessments, because many patients who, in
fact, were queried regarding pretreatment functional
status are reported as not in compliance due to lack of
documentation for all three domains. Once again, this
suggests that our ability to evaluate quality care, as
well as to detect different practice patterns among
urologists and radiation oncologists, may require re-
finement of certain quality indicators.
CONCLUSIONS
We have demonstrated the feasibility of measuring
compliance with the RAND candidate quality indica-
tors in a clinical hospital setting and have demon-
strated the ability of these indicators to detect changes
in quality of care over time. Future efforts to refine the
RAND indicators, develop benchmarks and to assess
quality of care on a larger scale have the potential to
lead to improved health outcomes for patients with
localized prostate carcinoma.
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